Q-Med Quarterly Report January - March 2003
May 12, 2003 10:15 ET
|
Q-Med
UPPSALA, Sweden, May 12, 2003 (PRIMEZONE) -- Q-Med:
Sales increased by 24 percent to SEK 141.3 (113.7) million. Adjusted for changes in exchange rates, sales increased by 33 percent.
On a rolling...
Q-Med has Received a First Payment of $58.2 Million from Medicis
March 10, 2003 03:38 ET
|
Q-Med
UPPSALA, Sweden, March 10, 2003 (PRIMEZONE) -- The American antitrust authority, Federal Trade Commission earlier approved Medicis (NYSE:MRX) acquisition of HA North American Sales AB from Q-Med...
The American Antitrust Authority Approves Medicis Acquisition of HA North American Sales AB from Q-Med
March 05, 2003 02:56 ET
|
Q-Med
UPPSALA, Sweden, March 5, 2003 (PRIMEZONE) -- The American antitrust authority, Federal Trade Commission, approves Medicis (NYSE:MRX) acquisition of HA North American Sales AB from Q-Med...
Q-Med: Report on Operations 2002
February 10, 2003 06:45 ET
|
Q-Med
UPPSALA, Sweden, Feb. 10, 2003 (PRIMEZONE) -- Q-Med (Stockholm:QMED):
-- Sales increased during the year by 36 percent to SEK 517.8 (380.2)
million. During the fourth quarter turnover...
The Q-Med Group Divests the North American Business Regarding the Esthetic Products RESTYLANE, RESTYLANE Fine Lines and PERLANE to Medicis for USD 160 million
February 10, 2003 05:13 ET
|
Q-Med
UPPSALA, Sweden, Feb. 10, 2003 (PRIMEZONE) -- The Q-Med Group (Stockholm:QMED) has signed an agreement to divest all shares in the wholly-owned subsidiary HA North American Sales AB to Medicis...
Q-Med Appoints Erika Kjellberg Eriksson as Chief Financial Officer
November 15, 2002 03:30 ET
|
Q-Med
UPPSALA, Sweden, Nov. 15, 2002 (PRIMEZONE) -- Erika Kjellberg Eriksson, who was appointed acting Chief Financial Officer at Q-Med (Stockholm:QMED) on September 24, has been appointed permanent Chief...
Q-Med Appoints Acting Chief Financial Officer
September 24, 2002 03:22 ET
|
Q-Med
UPPSALA, Sweden, Sept. 24, 2002 (PRIMEZONE) -- Erika Kjellberg Eriksson has been appointed acting Chief Financial Officer at Q-Med (Stockholm:QMED) and thereby replaces the former Chief Financial...
Q-Med: Half Year Report January-June 2002
August 22, 2002 06:05 ET
|
Q-Med
UPPSALA, Sweden, Aug. 22, 2002 (PRIMEZONE) -- Q-Med:
-Continued strong growth. Sales increased by 46 percent to SEK 253.4 (174.0) million. On a rolling 12-month basis sales rose by 51 percent to...
Application for RESTYLANE Submitted to the FDA
June 19, 2002 09:31 ET
|
Q-Med
UPPSALA, Sweden, June 19, 2002 (PRIMEZONE) -- The application for registration in order to obtain marketing approval in the U.S.A. has been submitted according to plan to the FDA (Food and Drug...
Q-Med: Clinical Study in the U.S.A Showed Clearly Significant Results in Favour of RESTYLANE.
May 06, 2002 04:28 ET
|
Q-Med
UPPSALA, Sweden, May 6, 2002 (PRIMEZONE) -- In the clinical study in the USA where the Swedish company Q-Med's* product RESTYLANE has been compared with a competing collagen-based product, the effect...